Polo Like Kinase 2 Tumour Suppressor and Cancer Biomarker: New Perspectives on Drug sensitivity/resistance in Ovarian Cancer

Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332.

Abstract

The polo-like kinase PLK2 has recently been identified as a potential theranostic marker in the management of chemotherapy sensitive cancers. The methylation status of the PLK2 CpG island varies with sensitivity to paclitaxel and platinum in ovarian cancer cell lines. Importantly, extrapolation of these in vitro data to the clinical setting confirms that the methylation status of the PLK2 CpG island predicts outcomes in patients treated with carboplatin and paclitaxel chemotherapy. A second cell cycle regulator, p57Kip2, is also subject to epigenetic silencing in carboplatin resistance in vitro and in vivo, emphasising that cell cycle regulators are important determinants of sensitivity to chemotherapeutic agents and providing insights into the phenomenon of collateral drug sensitivity in oncology. Understanding the mechanistic basis and identification of robust biomarkers to predict collateral sensitivity may inform optimal use of chemotherapy in patients receiving multiple lines of treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor* / genetics
  • Biomarkers, Tumor* / metabolism
  • Biomarkers, Tumor* / physiology
  • Carcinoma / genetics*
  • Carcinoma / pathology
  • Drug Resistance, Neoplasm / genetics*
  • Epigenesis, Genetic
  • Female
  • Gene Expression Regulation, Neoplastic / physiology
  • Genes, Tumor Suppressor* / physiology
  • Humans
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / pathology
  • Protein-Serine-Threonine Kinases / genetics
  • Protein-Serine-Threonine Kinases / metabolism
  • Protein-Serine-Threonine Kinases / physiology*

Substances

  • Biomarkers, Tumor
  • PLK2 protein, human
  • Protein-Serine-Threonine Kinases